Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, through its subsidiary and the largest ketamine therapy provider in the United States, Ketamine Wellness Centers (“KWC”), recently announced the expansion of its treatment options to include SPRAVATO(R) nasal spray for adults. The first FDA-approved ekestamine nasal spray for adults, SPRAVATO is made explicitly for treatment-resistant depression (“TRD”) along with the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions. A recent article reads, “While making the announcement, Kevin Nicholson, the CEO of KWC and COO of Delic, noted that the introduction of SPRAVATO underscores KWC’s commitment to providing clinically-backed, accessible, and affordable treatments to patients nationwide. He further pointed out that the company’s dedication to offering the highest quality service available, coupled with its vast network of ketamine clinics, allows it to serve more patients than any other ketamine therapy provider.”
To view the full article, visit https://ibn.fm/x8uU7
About Delic Holdings Corp.
Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses. For more information, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.